A Randomised, Double-Blind, Dose-Response Study with the HMG-CoA Reductase Inhibitor ZD4522 in Subjects with Hyperlipidaemis (A Phase II Clinical Study)

Study identifier:4522IL/0055

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomised, Double-Blind, Dose-Response Study with the HMG-CoA Reductase Inhibitor ZD4522 in Subjects with Hyperlipidaemis (A Phase II Clinical Study)

Medical condition

hypercholesterolaemia

Phase

N/A

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Interventional

Age

Date

Study Start Date: 01 Jan 1971

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2293&filename=CSR-4522IL-0055.pdf
Download
CSR-4522IL-0055.pdf
Download
Trial Results Summaries
Available here

A Randomised, Double-Blind, Dose-Response Study with the HMG-CoA Reductase Inhibitor ZD4522 in Subjects with Hyperlipidaemis (A Phase II Clinical Study)

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2293&filename=CSR-4522IL-0055.pdf

CSR-4522IL-0055.pdf

Trial Results Summaries